At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 252 enrolled
Drug / intervention
Pitavastatin +1 moredrug
Likely dose
Pitavastatin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study
In Brief
A Phase 4 clinical trial evaluating Pitavastatin and Pravastatin for Dyslipidemia. Completed, enrolled 252 participants across 35 sites.
Detailed Summary
A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesUnited States
CollaboratorsKowa Pharmaceuticals America, Inc., Eli Lilly and Company
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedFeb 2011
Primary CompletionMar 2013
TodayJul 2026
First PostedFeb 23, 2011
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.4 years ago
Interventions
Pitavastatindrug
Pitavastatin 4 mg QD
Pravastatindrug
Pravastatin 40 mg QD